Local treatment versus maintenance immunotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial compares two approaches after initial chemotherapy and immunotherapy for advanced non-small cell lung cancer: giving additional local treatment (like surgery or radiation) to remaining spots versus continuing immunotherapy. It aims to see which strategy better controls the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have stage IV non-small cell lung cancer that has spread.
- Your cancer does not have certain genetic changes (like EGFR or ALK).
- You have already completed 4-6 cycles of immunotherapy with chemotherapy and your cancer shrank or disappeared.
- You have some remaining active spots that can be treated with surgery, radiation, or ablation.
- You are generally in good health (able to care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
This trial tests combining chemotherapy, radiation therapy, and two immune-boosting drugs (iparomlimab and tuvonralimab) as a first treatment for locally advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination improves outcomes compared to standard care.
This trial tests whether adding local treatments like radiation or surgery to standard immunotherapy can help people with lung cancer that has spread to a few spots. It aims to see if this combination improves control of the disease.
This trial compares continuing drug therapy alone versus adding local treatments (surgery or radiation) for people with stage IV lung cancer that has responded to initial treatment but still has a few remaining spots (oligometastatic). The goal is to see if targeting those spots with local therapy helps control the cancer longer.
Hear when a new NSCLC (Non-small Cell Lung Carcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.